Cullinan Therapeutics Stock Quote CGEM - Stock Price, News, Charts, Message Board, Trades

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

17.47

Bid

17.47

Ask

17.51

Volume

300,907

16.98 Day's Range 18.40

7.64 52 Week Range 30.1886

Market Cap

1.013B

Previous Close

17.65

Open

18.00

Last Trade

100

17.47

Last Trade Time

10:38:34

Financial Volume

$ 5,271,141

VWAP

17.5175

Average Volume (3m)

679,167

Shares Outstanding

57,976,641

Dividend Yield

PE Ratio

-6.54

Earnings Per Share (EPS)

-2.64

Revenue

Net Profit

-153.16M

Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.cullinantherapeutics.com

Headquarters

Wilmington, Delaware, USA

Founded

Cullinan Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CGEM. The last closing price for Cullinan Therapeutics was $17.65. Over the last year, Cullinan Therapeutics shares have traded in a share price range of $ 7.64 to $ 30.1886.

Cullinan Therapeutics currently has 57,976,641 shares outstanding. The market capitalization of Cullinan Therapeutics is $1.02 billion. Cullinan Therapeutics has a price to earnings ratio (PE ratio) of -6.54.

Overall Flow

Bullish

Net Premium

428k

Calls / Puts

100.00%

Buys / Sells

50.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

Form 8-K - Current report

Cullinan Therapeutics Receives Approval to Initiate its Global Phase 1 Clinical Trial of CLN-978 for the Treatment of Systemic Lupus Erythematosus

Phase 1 clinical trial is designed to assess the safety, pharmacokinetics and initial clinical activity of CLN-978 for patients with systemic lupus erythematosus The trial will be conducted in...

Cullinan Therapeutics Announces Submission of Investigational New Drug Application to U.S. Food and Drug Administration for CLN-978 to Treat Systemic Lupus Erythematosus

CAMBRIDGE, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.39	2.28337236534	17.08	18.6199	15.91	1180763	17.72447049	CS
4	-1.39	-7.37009544008	18.86	19.89	15.91	680299	17.95434366	CS
12	1.01	6.13608748481	16.46	21.01	15.7	679167	17.93169726	CS
26	0.9	5.43150271575	16.57	30.1886	15.2	789555	20.15620979	CS
52	8.07	85.8510638298	9.4	30.1886	7.64	544986	18.37699462	CS
156	-5.58	-24.2082429501	23.05	30.1886	7.3	356786	15.49018125	CS
260	-24.53	-58.4047619048	42	59.85	7.3	338763	18.22703534	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
OCTOEightco Holdings Inc	$ 4.2599 (71.08%)	57.98M
SBCSBC Medical Group Holdings Incorporated	$ 10.18 (53.54%)	539.84k
MSGMMotorsport Games Inc	$ 1.49 (35.45%)	42.8M
TNONTenon Medical Inc	$ 5.25 (30.60%)	15.74M
RZLVRezolve AI Ltd	$ 6.10 (23.98%)	242.74k
VTNRVertex Energy Inc	$ 0.13 (-63.99%)	15.59M
CMCTCreative Media and Community Trust Corporation	$ 0.985 (-37.06%)	709.22k
SFIXStitch Fix Inc	$ 2.515 (-32.93%)	7.52M
BNZIBanzai International Inc	$ 6.05 (-26.58%)	1.62M
TOIIWOncology Institute Inc	$ 0.0113 (-20.42%)	4.01k
NVDANVIDIA Corporation	$ 124.31 (2.85%)	101.52M
CEROCERo Therapeutics Holdings Inc	$ 0.1125 (20.06%)	92.17M
MLGOMicroAlgo Inc	$ 0.2445 (13.09%)	64.26M
OCTOEightco Holdings Inc	$ 4.2599 (71.08%)	57.98M
SQQQProShares UltraPro Short QQQ	$ 7.43 (-2.88%)	43.46M